Search

KR-20260062222-A - Novel lactobacillus strains derived from human milk and uses thereof

KR20260062222AKR 20260062222 AKR20260062222 AKR 20260062222AKR-20260062222-A

Abstract

The present invention relates to a novel strain of the genus Lactobacillus isolated from breast milk. The Lactibacillus plantarum DH24 strain, deposited under the novel accession number KCCM13482P according to the present invention, exhibits excellent acid resistance, bile resistance, intestinal adhesion ability, and rapid metabolic activity, and can be usefully utilized as a probiotic composition.

Inventors

  • 황다현
  • 정재미
  • 김훈
  • 홍미진

Assignees

  • 호서대학교 산학협력단

Dates

Publication Date
20260507
Application Date
20241028

Claims (9)

  1. Lactiplantibacillus plantarum DH24 strain isolated from breast milk, deposited under accession number KCCM13482P.
  2. In Article 1, The Lactiplantibacillus plantarum DH24 strain deposited under the above deposit number KCCM13482P is a Lactiplantibacillus plantarum DH24 strain having a 16s rRNA sequence fragment containing the nucleotide sequence represented by SEQ ID NO. 1.
  3. In Article 1, The Lactiplantibacillus plantarum DH24 strain deposited under the above accession number KCCM13482P is characterized by having acid resistance.
  4. In Article 1, The Lactiplantibacillus plantarum DH24 strain deposited under the above accession number KCCM13482P is characterized by having bile resistance.
  5. In Article 1, The Lactiplantibacillus plantarum DH24 strain deposited under the above accession number KCCM13482P is characterized by having intestinal adhesion ability.
  6. In Article 1, The Lactiplantibacillus plantarum DH24 strain deposited under the above accession number KCCM13482P is characterized by exhibiting metabolic activity against one or more selected from the group consisting of amygdalin, D-celiobiose, D-melibiose, and gentiobiose when cultured for 10 to 15 hours.
  7. A probiotic composition comprising one or more selected from the group consisting of the Lactiplantibacillus plantarum DH24 strain deposited under accession number KCCM13482P, its culture medium, its extract, its lysate, its fraction, endoplasmic reticulum isolated therefrom, its fermented liquid, its dried product, its concentrate, and its cell-free supernatant.
  8. A food composition comprising one or more selected from the group consisting of the Lactiplantibacillus plantarum DH24 strain deposited under accession number KCCM13482P, its culture medium, its extract, its lysate, its fraction, endoplasmic reticulum isolated therefrom, its fermented liquid, its dried product, its concentrate, and its cell-free supernatant.
  9. A feed additive composition comprising one or more selected from the group consisting of the Lactiplantibacillus plantarum DH24 strain deposited under accession number KCCM13482P, its culture medium, its extract, its lysate, its fraction, endoplasmic reticulum isolated therefrom, its fermented liquid, its dried product, its concentrate, and its cell-free supernatant.

Description

Novel lactobacillus strains derived from human milk and uses thereof The present invention relates to a novel strain of the genus Lactibactinii derived from breast milk and its use. Lactic acid bacteria refers to bacteria that produce about 50% or more of lactic acid as a metabolic product for the sugars typically consumed. It is used conceptually as a general term for bacteria that produce a large amount of lactic acid from glucose and perform beneficial functions, such as preventing spoilage, without producing substances harmful to the human body, such as indole, skatole, phenol, amine, and ammonia, in food or in the intestines of humans and animals. Lactic acid bacteria, well-known as one of the probiotics, are recognized as GRAS (generally recognized safe) by the U.S. FDA and are used in various industries such as food, cosmetics, and pharmaceuticals, utilizing them for flavor, pH adjustment, and mineral enhancement. The term "probiotics" originates from the Greek word meaning "for life" and has its roots in an ecological term signifying a symbiotic relationship between living organisms. After undergoing several revisions, it is currently defined as "live bacteria in the form of single or multi-strain strains that provide beneficial effects by improving the intestinal flora of human or animal hosts when fed to humans or animals in the form of dried cells or fermentation products." In Korea, the term is currently used in three senses: it is labeled as "live bacteria" when used as a feed additive for animals, and as "intestinal regulators" or "lactic acid bacteria preparations" when used as a human pharmaceutical. Following the recognition of the efficacy of lactic acid bacteria as probiotics and numerous research reports, lactic acid bacteria preparations utilizing various strains have been developed and marketed in many countries. Currently, a wide variety of lactic acid bacteria preparations are sold in various nations, with the most commonly used strains belonging to the genera Lactobacillus acidophillus , L. casei , and Bifdobacterium . These strains are widely used because most of them can survive stomach acid and bile acid to reach the intestines. In Korea, after being first marketed in 1962, the market currently amounts to a total of 85 billion won annually, comprising approximately 70 billion won in the pharmaceutical sector, 4 to 5 billion won as feed additives, 8 billion won as lactic acid bacteria health supplements, and 3 billion won as starter cultures. However, since the production of raw materials requires the accumulation of technology regarding the selection of superior strains, strain management, cultivation, and formulation, the domestic production of lactic acid bacteria raw materials has not developed significantly. Currently, while some companies produce lactic acid bacteria raw materials, the reality is that most are imported from abroad and processed into formulations. Although belated, research on acid-resistant strains isolated from kimchi, fermented sauces, and salted seafood is underway in Korea, and while a diverse range of strains has been secured, the current situation still lags behind that of Japan and other Asian countries. Securing acid-resistant strains has the advantage of being usable in various fields, and possesses potential that is difficult to assess in terms of value, such as their role as oral vaccine carriers for humans and animals, their effect of enhancing intestinal immunity, the utility of metabolites within lactic acid bacteria, and their antimicrobial activity against resistant strains like superbugs. Therefore, there is a need for the development of novel strains with excellent acid resistance, bile resistance, and significant activity. Figure 1 is the result of confirming the sugar utilization characteristics of the Lactibactibacillus plantarum DH24 strain according to the present invention during 12 hours of culture. Figure 2 shows the results of confirming the sugar utilization characteristics of the Lactiplantibacillus plantarum DH24 strain according to the present invention during 12 and 24 hours of culture. Figure 3 shows the results of confirming the acid resistance and bile resistance of the Lactibacillus plantarum DH24 strain according to the present invention. Figure 4 shows the results of confirming the intestinal adhesion ability of the Lactiplantibacillus plantarum DH24 strain according to the present invention. In Figure 4, *** means p<0.001. Figure 5 shows the results of confirming the antibacterial activity of the Lactiplantibacillus plantarum DH24 strain according to the present invention against beneficial bacteria, namely Lactiplantibacillus plantarum (KCTC 3108) (L. planta) (Fig. 5(A)), Lacticaseibacillus rhamnosus GG (KCTC 5033), LGG) (Fig. 5(B)), Lactiplantibacillus pentosus (KCTC 3120), L. pento) (Fig. 5(C)), and Bifidobacterium longum (KACC 20597), B. longum) (Fig. 5(D)). FIG. 6 shows the harmful bacteria of the Lactiplantibacill